TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06931990: A Phase Ic/II Clinical Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of Multiple Oral Doses of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,960,550

Rescue Site Savings

+$1,951,770

Unlock Full NCT06931990 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06931990 Rescue Dossier →